MA38171B1 - Évaluation du risque d’insuffisance rénale aiguë suite a une chirurgie cardiaque - Google Patents

Évaluation du risque d’insuffisance rénale aiguë suite a une chirurgie cardiaque

Info

Publication number
MA38171B1
MA38171B1 MA38171A MA38171A MA38171B1 MA 38171 B1 MA38171 B1 MA 38171B1 MA 38171 A MA38171 A MA 38171A MA 38171 A MA38171 A MA 38171A MA 38171 B1 MA38171 B1 MA 38171B1
Authority
MA
Morocco
Prior art keywords
renal failure
acute renal
cardiac surgery
risk assessment
following cardiac
Prior art date
Application number
MA38171A
Other languages
English (en)
Other versions
MA38171A1 (fr
Inventor
Frank Dieterle
Holger Hoefling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA38171A1 publication Critical patent/MA38171A1/fr
Publication of MA38171B1 publication Critical patent/MA38171B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Artificial Intelligence (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)

Abstract

La présente invention concerne un procédé de prédiction de la gravité d'une insuffisance rénale aiguë suite à une chirurgie cardiaque.
MA38171A 2012-12-20 2013-12-18 Évaluation du risque d’insuffisance rénale aiguë suite a une chirurgie cardiaque MA38171B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740303P 2012-12-20 2012-12-20
PCT/EP2013/077253 WO2014096110A1 (fr) 2012-12-20 2013-12-18 Insuffisance rénale aiguë

Publications (2)

Publication Number Publication Date
MA38171A1 MA38171A1 (fr) 2016-11-30
MA38171B1 true MA38171B1 (fr) 2017-07-31

Family

ID=49885245

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38171A MA38171B1 (fr) 2012-12-20 2013-12-18 Évaluation du risque d’insuffisance rénale aiguë suite a une chirurgie cardiaque

Country Status (20)

Country Link
US (1) US20150309052A1 (fr)
EP (1) EP2936160A1 (fr)
JP (2) JP6416778B2 (fr)
KR (1) KR20150096728A (fr)
CN (1) CN104871004A (fr)
AR (1) AR094118A1 (fr)
AU (2) AU2013360685A1 (fr)
BR (1) BR112015014232A2 (fr)
CA (1) CA2895096A1 (fr)
CL (1) CL2015001768A1 (fr)
HK (1) HK1209838A1 (fr)
IL (1) IL239431A0 (fr)
MA (1) MA38171B1 (fr)
MX (1) MX2015008108A (fr)
PH (1) PH12015501399A1 (fr)
RU (1) RU2015129496A (fr)
SG (1) SG11201504329RA (fr)
TN (1) TN2015000263A1 (fr)
TW (1) TW201430347A (fr)
WO (1) WO2014096110A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019037043A1 (fr) * 2017-08-24 2019-02-28 菲鹏生物股份有限公司 Kit de détection d'une lésion rénale aiguë
CN108986915B (zh) * 2018-07-24 2021-07-06 戴松世 人工智能的急性肾损伤的早期预测方法和装置
WO2020064995A1 (fr) * 2018-09-28 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires permettant la prédiction d'une lésion rénale aiguë chez des patients atteints de diabète de type 2
KR20200042725A (ko) 2018-10-16 2020-04-24 (주) 솔 렌즈 프리 cmos 광자 어레이 센서의 노이즈 특성 평가 방법
US20220301711A1 (en) * 2019-06-11 2022-09-22 The Regents Of The University Of California Systems and Methods for Machine Learning-based Identification of Acute Kidney Injury in Trauma Surgery and Burned Patients
CN110441457A (zh) * 2019-08-02 2019-11-12 深圳市绿航星际太空科技研究院 一种检测尿液中同型半胱氨酸的方法
CN112114125A (zh) * 2020-08-27 2020-12-22 中国医学科学院北京协和医院 一种评估肾脏储备功能的方法和系统及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135147D1 (de) * 2000-10-17 2008-09-11 Besst Test Aps Nen biologischen zelle in einer körperflüssigkeitsprobe
US20040048274A1 (en) * 2000-10-17 2004-03-11 Morten Breindahl Assay for directly detecting an inflammatory indicator in a body fluid sample
US20040063160A1 (en) * 2000-10-17 2004-04-01 Lassen Michael Rud Assay for directly detecting a biological cell in a body fluid sample
US20090238812A1 (en) * 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early indentification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic surgery
CN102264230B (zh) * 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010057184A2 (fr) * 2008-11-17 2010-05-20 The Brigham And Women's Hospital, Inc. Procédés pour la détection de lésion rénale aiguë chez des humains
AU2009318813B2 (en) * 2008-11-21 2016-11-24 Future Medical Diagnostics Co., Ltd Methods, devices and kits for detecting or monitoring acute kidney injury
CN101706497A (zh) * 2009-11-05 2010-05-12 武汉三鹰生物技术有限公司 人tff3的elisa检测试剂盒
AU2010315008B2 (en) * 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2569631A4 (fr) * 2010-05-10 2013-12-04 Austin Health Marqueurs de lésion rénale aiguë
EP2661620A4 (fr) * 2011-01-08 2014-07-16 Astute Medical Inc Procédé et compositions pour diagnostiquer et pronostiquer une lésion rénale et une insuffisance rénale

Also Published As

Publication number Publication date
AU2017232081A1 (en) 2017-10-12
RU2015129496A (ru) 2017-01-26
MA38171A1 (fr) 2016-11-30
BR112015014232A2 (pt) 2017-07-11
CA2895096A1 (fr) 2014-06-26
CL2015001768A1 (es) 2015-10-09
TW201430347A (zh) 2014-08-01
CN104871004A (zh) 2015-08-26
IL239431A0 (en) 2015-07-30
HK1209838A1 (en) 2016-04-08
US20150309052A1 (en) 2015-10-29
MX2015008108A (es) 2015-11-06
JP6416778B2 (ja) 2018-10-31
WO2014096110A1 (fr) 2014-06-26
PH12015501399A1 (en) 2015-09-07
AU2013360685A1 (en) 2015-07-02
TN2015000263A1 (fr) 2016-10-03
SG11201504329RA (en) 2015-07-30
AR094118A1 (es) 2015-07-08
EP2936160A1 (fr) 2015-10-28
KR20150096728A (ko) 2015-08-25
JP2016503162A (ja) 2016-02-01
JP2019053067A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
MA38171B1 (fr) Évaluation du risque d’insuffisance rénale aiguë suite a une chirurgie cardiaque
CY1123172T1 (el) Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
FR3004421B1 (fr) Procedes pour predire une defaillance d'un systeme d'aerofreins
CR20150120A (es) Nuevos derivados bicíclicos
EA201200239A1 (ru) Бициклические арильные аналоги сфингозин 1-фосфата
BR112014001227A2 (pt) sistemas de monitoramento para determinação da condição de um objeto
BR112015028253A2 (pt) biomarcadores relacionados à função renal e métodos para utilização dos mesmos
CY1121382T1 (el) Ποσοτικοποιηση υπολειμματικων ενωσεων γλυκανης με μη-αναγωγικα ακρα
CR20140501A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
HK1208075A1 (en) Methods for predicting risk of developing hypertension
TR201904638T4 (tr) pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
FR3016052B1 (fr) Procede de determination d'une definition geometrique d'un equipement optique personnalise
FR3006776B1 (fr) Procede de determination d'au moins une valeur d'un parametre de personnalisation d'un equipement de compensation visuelle
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
FR3012952B1 (fr) Methode de determination d'au moins un parametre de conception optique d'une lentille ophtalmique progressive
BR112012016767A2 (pt) Método para diagnosticar se um paciente sofre de uma condição hepática ou do fígado, método para detectar o desenvolvimento de uma patologia do fígado, método para deter5 minar o risco de um paciente para uma condição do fígado e sistema para diagnosticar o estado de saúde hepática
FR2970030B1 (fr) Procede d'etancheite de rebord entre etages d'une turbine
EA201400940A1 (ru) Способ получения медетомидина
MA39185A1 (fr) Teledistribution d'une mise a jour logicielle a des terminaux de tele-releve
DK3002590T3 (da) En fremgangsmåde til at bestemme tilbøjeligheden til forkalkning
AU2012313353A8 (en) Screening method
BR112015018061A2 (pt) bloco de impacto refratário
FR3004808B1 (fr) Procede d'analyse d'un facies de rupture d'une piece de turbomachine